Repaglinide (Prandin) lowers long term cardiovascular complications of diabetes by working on reducing the postprandial glucose excursions by modulating early-phase insulin release. It has a rapid onset and relatively short duration of action allow for flexible meal schedules. Several studies have shown that repaglinide plus rosiglitazone was better than rosiglitazone alone, and repaglinide plus metformin had greater benefits to patients over nateglinide plus metformin.
Reference:
No comments:
Post a Comment